New diabetes leads: henagliflozin
Early reports suggest henagliflozin may have anti‑aging effects in T2D patients — the molecule reportedly impacts IGF‑1, glucose and immunity markers. (x.com) In preclinical work, palmatine eased fatty‑liver markers and inflammation — both signals that metabolic inflammation is still a major target area. (x.com)
Multicenter, randomized, double‑blind, placebo‑controlled trial in China assigned roughly 150 adults with type 2 diabetes to 10 mg/day henagliflozin or placebo for 26 weeks. (doi.org) The trial reported telomere-length increases in the treatment arm versus placebo — study summaries cite ~90.5% of henagliflozin patients showing telomere lengthening versus ~65.6% on placebo, with 124 participants completing primary assessments. (medicalxpress.com) (doi.org) Beyond telomeres, the study measured shifts in growth‑factor and metabolite markers: insulin‑like growth factor‑binding protein‑3 (IGFBP‑3) and β‑hydroxybutyrate rose and circulating thiamine increased after 26 weeks on henagliflozin. (sciencedirect.com) Immune‑function assays in the supplement showed higher perforin and granzyme B expression in cytotoxic T lymphocytes and NK cells after treatment, and continuous‑glucose‑monitoring data recorded improved time‑in‑range metrics versus placebo. (cell.com)00404-5) (cell.com) A preclinical study accepted to Scientific Reports (accepted 19 March 2026) tested palmatine in rat models of T2DM‑associated MASLD and identified five core hepatic targets: ADRB2, BCL3, EGR1, FOS and MAP3K8. (nature.com) In the rat experiments palmatine treatment lowered serum ALT and AST, reduced pro‑inflammatory cytokines TNF‑α and IL‑6, increased antioxidant markers SOD and GSH, reduced total cholesterol/triglycerides/LDL‑C and improved histologic steatosis and fibrosis scores. (news-medical.net) (nature.com)
